- Home
- UBCP vs HURA Comparison
UBCP vs HURA Comparison
Compare UBCP & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | UBCP | HURA |
|---|---|---|
| Founded | 1902 | 2009 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 79.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | UBCP | HURA |
|---|---|---|
| Price | $15.36 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 5.3K | ★ 726.1K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.11% | N/A |
| EPS Growth | ★ 5.51 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.44 | $0.41 |
| 52 Week High | $17.34 | $4.41 |
Technical Indicators
Market Signals| Indicator | UBCP | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 43.11 |
| Support Level | $13.32 | $1.02 |
| Resistance Level | $15.75 | $1.55 |
| Average True Range (ATR) | 0.97 | 0.20 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 22.35 | 25.14 |
Price Performance
Historical ComparisonAbout UBCP United Bancorp Inc.
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.